CG Invites Co

CG Invites Co EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of CG Invites Co (083790.KQ) as of Nov 1, 2026 is -6.76. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -4.39 — a change of 53.88% (lower).

EV/OCF

-6.76

YoY

53.88%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of CG Invites Co is 2025 -6.76 . EV/OCF (Enterprise Value to Operating Cash Flow) of CG Invites Co was 2024 -4.39 . It decreases by 53.88% lower compared to the previous year.

The CG Invites Co EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
7.18 KRW
Jan 1, 2019
-3.29 KRW
Jan 1, 2020
-1.89 KRW
Jan 1, 2021
-5.03 KRW
Jan 1, 2022
-4.11 KRW
Jan 1, 2023
-4.55 KRW
Jan 1, 2024
-4.39 KRW
Jan 1, 2025
-6.76 KRW
The CG Invites Co EV/OCF history
YEAREV/OCFYoY
-6.76+53.88%
-4.39-3.45%
-4.55+10.56%
-4.11-18.16%
-5.03+166.23%
-1.89-42.64%
-3.29-145.87%
7.18-88.28%
61.24-572.48%
-12.96-51.01%
-26.46-39.86%
-43.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG Invites Co Stock analysis

What does CG Invites Co do? CrystalGenomics, Inc. generates revenue through its Finished Pharmaceuticals Manufacturing segment, which produces and sells finished pharmaceuticals. The Pharmaceutical R&D Division provides clinical trial analysis and technical services while also selling new drugs. The company also operates in the real estate leasing business under the segment structure. The Others segment manufactures and sells hot fats and other household items. Revenue streams are derived from pharmaceutical manufacturing, R&D services, real estate leasing, and household product sales. The primary buyers for finished pharmaceuticals include healthcare providers and distributors. Clinical trial analysis and new drug sales target pharmaceutical companies and research institutions. Real estate leasing serves commercial tenants, while hot fats and household items are sold to retail consumers. The company's segments collectively serve diverse markets across healthcare, real estate, and consumer goods. CrystalGenomics, Inc. focuses on therapeutic discovery and development, with its R&D Division driving innovation in new drug sales. The Finished Pharmaceuticals Manufacturing segment ensures steady supply of established products. Real estate leasing and household item sales provide additional revenue streams. The company's business model integrates pharmaceutical production, research, and non-pharmaceutical ventures. CG Invites Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CG Invites Co stock

EV/OCF (Enterprise Value to Operating Cash Flow) of CG Invites Co is -6.76 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of CG Invites Co changed from -4.39 to -6.76, representing a 53.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) CG Invites Co since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s CG Invites Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — CG Invites Co

All Key Metrics — CG Invites Co